Anixa Biosciences CEO buys 3,000 shares at $2.75

Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased additional Common Stock in the company.

Rhea-AI Filing Summary

Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased additional Common Stock in the company. On September 10, 2026, he bought 3,000 shares in an open-market or private transaction at $2.75 per share, bringing his directly held stake to 665,000 shares. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 3,000 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 3,000 shs ($8K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,000	$2.75	$8K

Holdings After Transaction: Common Stock — 665,000 shares (Direct)

Key Figures

Shares purchased: 3,000 shares Purchase price: $2.75 per share Shares owned after transaction: 665,000 shares +1 more

4 metrics

Shares purchased 3,000 shares Common Stock acquired on September 10, 2026

Purchase price $2.75 per share Open-market or private transaction on September 10, 2026

Shares owned after transaction 665,000 shares Directly held Common Stock following the reported purchase

Net buy shares 3,000 shares Net buy direction across all transactions in this Form 4

Key Terms

Common Stock, open-market or private transaction, Rule 10b5-1

3 terms

Common Stock financial

"Amit Kumar purchased additional Common Stock in the company."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market or private transaction financial

"he bought 3,000 shares in an open-market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIX report for Amit Kumar?

Amit Kumar reported a purchase of 3,000 shares of Anixa Biosciences Common Stock on September 10, 2026, in an open-market or private transaction at $2.75 per share, increasing his directly held stake to 665,000 shares.

How many ANIX shares does the CEO hold after this Form 4 transaction?

After the reported transaction, Amit Kumar directly holds 665,000 shares of Anixa Biosciences Common Stock, according to the Form 4 filing.

At what price were the ANIX shares purchased in this Form 4?

The reported purchase price was $2.75 per share for the 3,000 Anixa Biosciences Common Stock shares acquired on September 10, 2026.

Was the ANIX insider trade made under a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not affirmed, so there is no Rule 10b5-1 trading plan reported for this transaction.

Is Amit Kumar’s ownership in ANIX direct or indirect after this trade?

The Form 4 shows direct ownership of 665,000 Anixa Biosciences Common Stock shares following the purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 09:45 AM Accepted by SEC EDGAR 09/14/2026 - 09:45 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		P		3,000	A	$2.75	665,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)